Posters
Presenting Author Academic/Professional Position
Resident
Academic Level (Author 1)
Resident
Discipline/Specialty (Author 1)
Internal Medicine
Academic Level (Author 2)
Resident
Discipline/Specialty (Author 2)
Internal Medicine
Academic Level (Author 3)
Faculty
Discipline/Specialty (Author 3)
Internal Medicine
Presentation Type
Poster
Discipline Track
Community/Public Health
Abstract Type
Research/Clinical
Abstract
Introduction: The incidence of liver and intrahepatic bile duct carcinomas has risen significantly in the United States, necessitating a deeper understanding of survival outcomes and prognostic determinants. This study examines survival rates based on disease stage at diagnosis and explores the influence of demographic factors such as sex, race, ethnicity, and age.
Objectives: The primary objective is to evaluate survival rates stratified by disease stage and demographic variables using data from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2021.
Methods: Data were extracted from the SEER database for patients diagnosed with primary hepatic and intrahepatic bile duct carcinomas from 2004 to 2021. Survival outcomes were analyzed by disease stage at diagnosis, categorized as localized, regional, distant, and unstaged. Additional analyses focused on demographic factors including sex, race, ethnicity, and age groups.
Results:
Survival by Stage at Diagnosis:
The 5-year relative survival rates demonstrated a clear dependency on the stage of diagnosis:
-
Localized: 37.3%
-
Regional: 13%
-
Distant: 3.3%
-
Unstaged: 10.4%
These results underscore the importance of early detection, as survival rates decline sharply with advanced-stage diagnoses.
Survival by Sex:
Females exhibited a modest but consistent survival advantage over males:
-
At diagnosis: 20.0% for females vs. 18.5% for males
-
After 1 year: 39.5% for females vs. 37.3% for males
-
After 3 years: 60.9% for females vs. 57.9% for males
-
After 5 years: 73.3% for females vs. 70.8% for males
These findings suggest sex-specific factors may influence prognosis and warrant further investigation.
Survival by Race and Ethnicity:
Significant disparities in survival rates were observed among racial and ethnic groups:
-
Non-Hispanic Asian/Pacific Islanders: Highest survival rates (26.3% at diagnosis, 74.9% at 5 years).
-
Non-Hispanic Black patients: Lowest survival rates (16% at diagnosis, 54.7% at 5 years).
-
Hispanic patients: Intermediate rates (35% after 1 year).
-
Non-Hispanic American Indian/Alaska Native patients: 70% survival at 5 years.
These disparities highlight the urgent need for equitable healthcare access and targeted interventions.
Survival by Age:
Age at diagnosis had a significant impact on survival outcomes:
-
Patients under 50 years: Survival rate of 29.2% at diagnosis, rising to 82.6% at 5 years.
-
Patients aged 65 and older: Survival rate of 14.5% at diagnosis, increasing to 60.1% at 5 years.
These findings emphasize the importance of age-specific treatment strategies.
Relationship Between Diagnosis Timing and Disease Stage:
Survival rates progressively decline with advancing disease stages:
-
Localized stage: Demonstrates significantly better outcomes, even over 10 years.
-
Regional stage: Sharp drop in survival after the first year.
-
Distant stage: Poorest prognosis, with a 10-year survival rate of just 2.2%.
Discussion: The study highlights substantial variability in survival outcomes based on disease stage and demographic factors. Early-stage diagnosis is strongly associated with significantly improved survival rates, emphasizing the critical importance of prompt detection and intervention. However, a noteworthy proportion—exceeding one-third—of individuals diagnosed with early-stage intrahepatic cholangiocarcinoma did not receive curative treatments. This disparity is particularly pronounced among Hispanic and Black populations, who demonstrated a significantly lower likelihood of undergoing curative interventions compared to their White counterparts. These findings underscore the urgent need for individualized treatment strategies and targeted efforts to ensure equitable access to care, aiming to reduce these demographic disparities and improve outcomes for all patient groups.
Conclusion: Early identification and accurate staging of liver and intrahepatic bile duct carcinomas are pivotal for improving survival outcomes. Addressing demographic disparities through targeted interventions and ensuring equitable healthcare access are essential for optimizing patient care and achieving better overall prognoses.
Recommended Citation
Calderon, Aura; Mogollon, Ivan; and Cobos, Everardo, "Prognostic Determinants of Liver and Intrahepatic Bile Duct Carcinomas: A SEER Database Analysis" (2025). Research Symposium. 28.
https://scholarworks.utrgv.edu/somrs/2025/posters/28
Included in
Prognostic Determinants of Liver and Intrahepatic Bile Duct Carcinomas: A SEER Database Analysis
Introduction: The incidence of liver and intrahepatic bile duct carcinomas has risen significantly in the United States, necessitating a deeper understanding of survival outcomes and prognostic determinants. This study examines survival rates based on disease stage at diagnosis and explores the influence of demographic factors such as sex, race, ethnicity, and age.
Objectives: The primary objective is to evaluate survival rates stratified by disease stage and demographic variables using data from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2021.
Methods: Data were extracted from the SEER database for patients diagnosed with primary hepatic and intrahepatic bile duct carcinomas from 2004 to 2021. Survival outcomes were analyzed by disease stage at diagnosis, categorized as localized, regional, distant, and unstaged. Additional analyses focused on demographic factors including sex, race, ethnicity, and age groups.
Results:
Survival by Stage at Diagnosis:
The 5-year relative survival rates demonstrated a clear dependency on the stage of diagnosis:
-
Localized: 37.3%
-
Regional: 13%
-
Distant: 3.3%
-
Unstaged: 10.4%
These results underscore the importance of early detection, as survival rates decline sharply with advanced-stage diagnoses.
Survival by Sex:
Females exhibited a modest but consistent survival advantage over males:
-
At diagnosis: 20.0% for females vs. 18.5% for males
-
After 1 year: 39.5% for females vs. 37.3% for males
-
After 3 years: 60.9% for females vs. 57.9% for males
-
After 5 years: 73.3% for females vs. 70.8% for males
These findings suggest sex-specific factors may influence prognosis and warrant further investigation.
Survival by Race and Ethnicity:
Significant disparities in survival rates were observed among racial and ethnic groups:
-
Non-Hispanic Asian/Pacific Islanders: Highest survival rates (26.3% at diagnosis, 74.9% at 5 years).
-
Non-Hispanic Black patients: Lowest survival rates (16% at diagnosis, 54.7% at 5 years).
-
Hispanic patients: Intermediate rates (35% after 1 year).
-
Non-Hispanic American Indian/Alaska Native patients: 70% survival at 5 years.
These disparities highlight the urgent need for equitable healthcare access and targeted interventions.
Survival by Age:
Age at diagnosis had a significant impact on survival outcomes:
-
Patients under 50 years: Survival rate of 29.2% at diagnosis, rising to 82.6% at 5 years.
-
Patients aged 65 and older: Survival rate of 14.5% at diagnosis, increasing to 60.1% at 5 years.
These findings emphasize the importance of age-specific treatment strategies.
Relationship Between Diagnosis Timing and Disease Stage:
Survival rates progressively decline with advancing disease stages:
-
Localized stage: Demonstrates significantly better outcomes, even over 10 years.
-
Regional stage: Sharp drop in survival after the first year.
-
Distant stage: Poorest prognosis, with a 10-year survival rate of just 2.2%.
Discussion: The study highlights substantial variability in survival outcomes based on disease stage and demographic factors. Early-stage diagnosis is strongly associated with significantly improved survival rates, emphasizing the critical importance of prompt detection and intervention. However, a noteworthy proportion—exceeding one-third—of individuals diagnosed with early-stage intrahepatic cholangiocarcinoma did not receive curative treatments. This disparity is particularly pronounced among Hispanic and Black populations, who demonstrated a significantly lower likelihood of undergoing curative interventions compared to their White counterparts. These findings underscore the urgent need for individualized treatment strategies and targeted efforts to ensure equitable access to care, aiming to reduce these demographic disparities and improve outcomes for all patient groups.
Conclusion: Early identification and accurate staging of liver and intrahepatic bile duct carcinomas are pivotal for improving survival outcomes. Addressing demographic disparities through targeted interventions and ensuring equitable healthcare access are essential for optimizing patient care and achieving better overall prognoses.
